Journal
IMMUNOTHERAPY
Volume 11, Issue 6, Pages 543-554Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0186
Keywords
adverse events; atezolizumab; chemotherapy; nivolumab; pembrolizumab
Categories
Ask authors/readers for more resources
Aim: This study aims to clarify toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations. Methods: Eligible studies included randomized studies evaluating chemotherapy with or without an immune checkpoint inhibitor (including pembrolizumab, nivolumab, atezolizumab, durvalumab or avelumab). The primary summary statistic was the relative risk (RR). Results: A total of 11 studies were finally included into this meta-analysis. RRs of high-grade anemia, thrombocytopenia and neutropenia were 0.98 (95% CI: 0.83-1.16; p = 0.84), 1.10 (95% CI: 0.83-1.47; p = 0.51) and 0.96 (0.78-1.17; p = 0.66), respectively. RR of high-grade nausea, vomiting and diarrhea was 1.19 (95% CI: 0.78-1.82; p = 0.42), 1.09 (95% CI: 0.69-1.72; p = 0.71) and 2.61 (1.42-4.79; p = 0.002), respectively. Conclusion: Addition of immune checkpoint inhibitors to chemotherapy backbone does not increase the risk of high-grade hematological or gastrointestinal toxicities (except for high-grade diarrhea).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available